{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=103&state=Michigan",
    "query": {
      "state": "Michigan",
      "city": "Detroit",
      "page": 103
    },
    "page_size": 10
  },
  "pagination": {
    "page": 103,
    "page_size": 10,
    "total_count": 7251,
    "total_pages": 726,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=104&state=Michigan&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=102&state=Michigan&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-22T09:44:06.146Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02556788",
      "title": "Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "CD5789 (trifarotene) 50µg/g Cream",
          "type": "DRUG"
        },
        {
          "name": "Placebo Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "9 Years and older"
      },
      "enrollment_count": 1212,
      "start_date": "2015-11",
      "completion_date": "2017-05-12",
      "has_results": true,
      "last_update_posted_date": "2019-11-12",
      "last_synced_at": "2026-11-22T09:44:06.146Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02556788"
    },
    {
      "nct_id": "NCT01482403",
      "title": "A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "Copegus",
          "type": "DRUG"
        },
        {
          "name": "Pegasys",
          "type": "DRUG"
        },
        {
          "name": "boceprevir",
          "type": "DRUG"
        },
        {
          "name": "mericitabine",
          "type": "DRUG"
        },
        {
          "name": "mericitabine placebo",
          "type": "DRUG"
        },
        {
          "name": "boceprevir placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2011-11",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2016-08-05",
      "last_synced_at": "2026-11-22T09:44:06.146Z",
      "location_count": 7,
      "location_summary": "Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more",
      "locations": [
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01482403"
    },
    {
      "nct_id": "NCT03709342",
      "title": "A PK/PD Study of CM4620-IE in Patients With Acute Pancreatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Pancreatitis"
      ],
      "interventions": [
        {
          "name": "CM4620-IE",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CalciMedica, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2019-01-06",
      "completion_date": "2019-06-07",
      "has_results": true,
      "last_update_posted_date": "2022-05-03",
      "last_synced_at": "2026-11-22T09:44:06.146Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03709342"
    },
    {
      "nct_id": "NCT00679354",
      "title": "Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Childhood High-grade Cerebellar Astrocytoma",
        "Childhood High-grade Cerebral Astrocytoma",
        "Recurrent Childhood Anaplastic Astrocytoma",
        "Recurrent Childhood Anaplastic Oligoastrocytoma",
        "Recurrent Childhood Anaplastic Oligodendroglioma",
        "Recurrent Childhood Brain Tumor",
        "Recurrent Childhood Cerebellar Astrocytoma",
        "Recurrent Childhood Cerebral Astrocytoma",
        "Recurrent Childhood Glioblastoma",
        "Recurrent Childhood Visual Pathway and Hypothalamic Glioma"
      ],
      "interventions": [
        {
          "name": "cilengitide",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 30,
      "start_date": "2008-06",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2018-08-01",
      "last_synced_at": "2026-11-22T09:44:06.146Z",
      "location_count": 19,
      "location_summary": "Oakland, California • San Francisco, California • Washington D.C., District of Columbia + 16 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00679354"
    },
    {
      "nct_id": "NCT05100862",
      "title": "A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsed/Refractory Follicular Lymphoma",
        "Marginal Zone Lymphoma"
      ],
      "interventions": [
        {
          "name": "Zanubrutinib",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Obinutuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BeOne Medicines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 799,
      "start_date": "2022-03-10",
      "completion_date": "2030-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-11-22T09:44:06.146Z",
      "location_count": 50,
      "location_summary": "Fresno, California • Irvine, California • Los Alamitos, California + 43 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05100862"
    },
    {
      "nct_id": "NCT00475605",
      "title": "A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "LEO Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "Up to 16 Years"
      },
      "enrollment_count": 8071,
      "start_date": "2005-05-25",
      "completion_date": "2019-01-31",
      "has_results": false,
      "last_update_posted_date": "2019-12-18",
      "last_synced_at": "2026-11-22T09:44:06.146Z",
      "location_count": 198,
      "location_summary": "Alabaster, Alabama • Anniston, Alabama • Birmingham, Alabama + 155 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00475605"
    },
    {
      "nct_id": "NCT00005027",
      "title": "Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "becatecarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-06",
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2013-04-05",
      "last_synced_at": "2026-11-22T09:44:06.146Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005027"
    },
    {
      "nct_id": "NCT05633654",
      "title": "Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Sacituzumab govitecan-hziy (SG)",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1514,
      "start_date": "2022-12-12",
      "completion_date": "2031-08",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-22T09:44:06.146Z",
      "location_count": 188,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 158 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Prescott Valley",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05633654"
    },
    {
      "nct_id": "NCT00913094",
      "title": "Bioimpedance Evaluation of Therapeutic Titration in Essential, Refractory Hypertension",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "CardioDynamics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2009-01",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2009-06-11",
      "last_synced_at": "2026-11-22T09:44:06.146Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00913094"
    },
    {
      "nct_id": "NCT00002646",
      "title": "Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "fenretinide",
          "type": "DRUG"
        },
        {
          "name": "tamoxifen citrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 1500,
      "start_date": "1995-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-01-05",
      "last_synced_at": "2026-11-22T09:44:06.146Z",
      "location_count": 85,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002646"
    }
  ]
}